Loading cancer entity…
Loading cancer entity…
Clinical trials
242 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (46)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04709458 | Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | unknown | Phase 1 | 10 | Taiga Biotechnologies, Inc.INDUSTRY | 2 | May 3, 2022 | clinicaltrials |
| NCT01298934 | LBH589 (Panobinostat) for the Treatment of Myelofibrosis | unknown | Phase 1 / Phase 2 | 22 | Ronald HoffmanOTHER | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00668421 |
| CEP-701 (Lestaurtinib) in Myelofibrosis |
| unknown |
| Phase 1 / Phase 2 |
| 60 |
| Ronald HoffmanOTHER |
| 1 |
| Nov 26, 2014 |
| clinicaltrials |
Data updated 22 days agoSource updated May 3, 2022source: clinicaltrials